MEK inhibitors - novel targeted therapies of neurofibromatosis associated benign and malignant lesions

Abstract MAP/ERK kinase 1 and 2 (MEK 1/2) inhibitors (MEKi) are investigated in several trials to treat lesions that arise from pathogenic variants of the Neurofibromatosis type 1 and type 2 genes (NF1, NF2). These trials showed that MEKi are capable to shrink volume of low grade gliomas and plexifo...

Celý popis

Podrobná bibliografie

Hlavní autor:	Anja Harder
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2021-04-01
Edice:	Biomarker Research
Témata:	MEK inhibitor Neurofibromatosis NF1 NF2 Schwannomatosis LGG
On-line přístup:	https://doi.org/10.1186/s40364-021-00281-0
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!